The enhanced clinical efficacy of Thymoglobulin was explained by higher affinity of rabbit IgG subtype to human lymphocytes, less batch-to-batch variability, longer half-life, and more profound and longer lasting lymphocyte depletion compared to horse ATG.[ 27 ] Due to less frequent treatments of recurrent rejection and less frequent return to dialysis, Thymoglobulin provided significant cost savings.[ 28 ] A randomized clinical trial comparing Thymoglobulin (n=31) and OKT 3 (n=29) in treatment of steroid resistant acute rejection in kidney transplant patients showed a trend in favor of Thymoglobulin (13% vs. 23% overall graft failures; 89% vs. 81% 1-year graft survival).
1
—
—